drugset / Trial / NCT03005860

Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery

NCT03005860

RandomizedParallel-groupTriple-blindSupportive care

Summary

Surgery, perioperative stress, anaesthetics and analgesics may modulate the immunosurveillance mechanisms and overwhelm host defences that normally maintain a balance between immunity \& carcinogenesis. This may lead to escape of cancer cells and tilt the scales toward a more protumorigenic microenvironment. Volatile agents, in particular, have been shown to exhibit profound immunosuppressive effects. In comparison, propofol has a favorable profile and inhibits cancer cell activity. Determining "cancer-protective" role of TIVA with propofol presents an exciting window of opportunity that has potential to improve outcomes in cancer patients undergoing resection surgery

Timeline

Start
2017-01-01
Primary completion
2020-10
Completion
2020-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 2,6-Diisopropylphenol Unknown Intravenous
Comparator Sevoflurane Other / unclassified Inhaled
Background Atracurium Small molecule 0.5 mg/kg
Background Fentanyl Other / unclassified 2 ug/kg

Indications